PRESS RELEASE published on 03/19/2025 at 12:30, 1 year 7 months ago Informations privilégiées / Autres communiqués Rapport du conseil d'administration de VALERIO THERAPEUTICS pour l'AG mixte des actionnaires du 9 avril 2025 concernant révocations, cooptations, division du nominal des actions et modifications statutaires Cooptation Revocation Valerio Therapeutics AG Mixte Division Du Nominal
PRESS RELEASE published on 03/19/2025 at 12:30, 1 year 7 months ago Inside Information / Other news releases Valerio Therapeutics Board of Directors convenes a General Meeting with resolutions on director dismissals, co-optation, share division, bylaws amendment, and formalities powers Board Of Directors General Meeting Resolutions Valerio Therapeutics Share Division
BRIEF published on 02/04/2025 at 10:40, 1 year 9 months ago Valerio Therapeutics opts for strategic refocusing Clinical Trials Oncology Financial Strategy Medical Innovation Valerio Therapeutics
BRIEF published on 02/04/2025 at 10:40, 1 year 9 months ago Valerio Therapeutics opte pour un recentrage stratégique Innovation Médicale Stratégie Financière Essais Cliniques Oncologie Valerio Therapeutics
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year 9 months ago Inside Information / Other news releases Valerio Therapeutics refocuses strategy, discontinuing clinical trials for financial reasons. Focus on early-stage drug development Clinical Trials Financial Challenges Valerio Therapeutics Strategy Refocus Early-stage Development
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year 9 months ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce un recentrage stratégique pour se concentrer sur le développement de médicaments early-stage et assurer une croissance durable. La société cherche un accord de financement à long terme Développement Financement Restructuration Médicaments Valerio Therapeutics
BRIEF published on 10/01/2024 at 00:56, 2 years 1 month ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
BRIEF published on 10/01/2024 at 00:56, 2 years 1 month ago Valerio Therapeutics publie ses résultats financiers du premier semestre 2024 Résultats Financiers R&D Essai Clinique Valerio Therapeutics Anticorps À Domaine Unique
PRESS RELEASE published on 10/01/2024 at 00:51, 2 years 1 month ago Inside Information: News release on accounts, results Valerio Therapeutics annonce ses résultats financiers du Premier Semestre 2024 et fait le point sur ses activités, y compris l'acquisition d'Emglev Therapeutics et le développement de la plateforme PlatONTM Résultats Financiers Biotechnologie Valerio Therapeutics Emglev Therapeutics Plateforme PlatONTM
BRIEF published on 10/01/2024 at 00:45, 2 years 1 month ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
Published on 11/14/2026 at 01:30, 2 hours 25 minutes ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 3 hours 15 minutes ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 3 hours 20 minutes ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 3 hours 55 minutes ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:15, 4 hours 40 minutes ago Core Critical Metals Corp. Announces $500,000 Non-Brokered Critical Mineral Flow-Through Private Placement
Published on 11/13/2026 at 23:24, 4 hours 30 minutes ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 6 hours 2 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 8 hours 46 minutes ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 8 hours 55 minutes ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 16 hours 19 minutes ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 16 hours 19 minutes ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 19 hours 55 minutes ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 1 day 4 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
